. 2020 Oct 21;19:1533033820957030. doi: 10.1177/1533033820957030

Table 1.

Comparison of Clinicopathological Parameters and Survival Outcome Indicators between LUAD Patients with High and Low PLEK2 Expression.

Parameters		PLEK2 expression		p value
Parameters		High (N = 252)	Low (N = 252)	p value
Age (Mean ± SD)		65.56 ± 10.63	65.00 ± 9.40	0.54
Gender	Female	136	134	0.93
Gender	Male	116	118	0.93
Smoking History	2/3/4/5	41	31	0.20
	1	202	215	0.20
	no data	9	6
Pathological Stage	I/II	186	204	0.06
	IIIV	62	44	0.06
	Discrepancy/no data	4	4
Pathological T status	T1/T2	215	222	0.28
	T3/T4	36	27	0.28
	TX/no data	1	3
Pathological N status	N0	144	179	<0.001
	N1/2/3	104	64	<0.001
	NX/no data	4	9
Pathological M status	M0	160	175	0.69
	M1	13	12	0.69
	MX/no data	79	65
Residual tumors	R0	171	163	0.075
	R1/R2	12	4	0.075
	RX/no data	69	85
OS status	Living	143	178	0.002
OS status	Dead	109	74	0.002
PFS status	No progression	136	162	0.023
PFS status	Progression	116	90	0.023
DSS status	Living	165	192	0.005
	Disease-specific death	69	43	0.005
	no data	18	17
DFS status	Disease-free	92	119	0.023
	Progression	52	37	0.023
	no data	108	96

Smoking history: 1: lifelong non-smoker; 2: current smoker; 3. Current reformed smoker (for >15 yrs); 4. Current reformed smoker (for ≤15 yrs); 5. Current reformed smoker (duration not specified); TX: Primary tumor cannot be assessed; NX: Regional lymph nodes cannot be assessed; MX: Presence of distant metastasis cannot be assessed; RX: The presence of residual tumor cannot be assessed. Bold: p < 0.05